

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Croll-Kalish et al.

Serial No.: to be assigned **Group:** to be assigned

Filing Date: Concurrently Herewith **Examiner:** to be assigned

Title: CIRL3-Like Proteins, Nucleic Acids, and Methods of Modulating
CIRL3-L-Mediated Activity

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.


This Information Disclosure Statement is being filed:

- [X] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Fees

No fee is required for the filing of this Information Disclosure Statement.
If any additional fee should be deemed necessary, the Commissioner is hereby
authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 1030A
Serial No. : to be assigned
Applicant: : Croll-Kalish
Date Filed : Concurrently herewith
For : CIRL3-LIKE PROTEINS, NUCLEIC
ACIDS, AND METHODS OF
MODULATING CIRL3-L-MEDIATED
ACTIVITY

Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner
Initials

_____ NCBI, AAC77816, Calcium-independent alpha-latrotoxin receptor homolog 3 (Rattus norvegicus), J. Biol. Chem. 274 (9), 5491-5498 (1999).

_____ Bittner, M.A., et al., The Journal of Neurosciences, Vol. 18, No. 8, pp. 2914-2922, (1988).

_____ Krasnoperov, V.G., et al., Neuron, Vol. 18, pp. 925-937.


EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:


Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400